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Atypical manifestations of granulomatosis with polyangiitis:  
the diagnostic challenge for pulmonologists
Abstract
This is a review considering atypical manifestations of granulomatosis with polyangiitis (GPA). Virtually any organ can be affected, 
and in some patients, GPA can manifest unusually. Since thoracic involvement of GPA often predominates, the first who might 
be expected to establish a diagnosis are pulmonary specialists. We would like to familiarize pulmonary specialists with several 
extra-ELK (E: ear-nose-throat; L: lung; K: kidney) involvements of the disease. We describe sites rarely affected by GPA like the 
breast, skeletal system, orbit and eye, heart and vessels, central nervous system, urogenital system as well as endocrine and 
gastrointestinal tract involvement. 
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Introduction
Granulomatosis with polyangiitis (GPA) is an 
uncommon necrotizing inflammation of small ar-
teries and veins (vasculitis). It classically involves 
the vessels of the lungs, nasal passages, ear, throat 
and kidneys, and clinically manifests as a triad 
consisting of upper and lower airway disorders 
and glomerulonephritis. GPA can affect people 
at any age, although it is uncommon in children. 
Usually, GPA affects young or middle-aged adults. 
The cause of GPA remains unknown. However, 
the association of small vessel vasculitis with 
antineutrophil cytoplasmic antibodies, which 
are usually specific for proteinase 3, has yielded 
a new insight into pathogenic mechanisms [1]. 
Treatment depends on the extent of involvement 
and clinical course. In modern treatment strate-
gies, intensive immunosuppressive therapy with 
a high dose of corticosteroids and cyclophospha-
mide or rituximab are used to induce remission 
[2, 3]. Once remission is achieved, patients are 
switched to less toxic maintenance immunosup-
pression, such as azathioprine and a low dose of 
corticosteroids. Normally, GPA responds quickly 
to immunosuppressive therapy, and prognosis, 
mainly limited by renal and pulmonary involve-
ment, is rather good without higher mortality.
The wide range of clinical presentations is 
encompassed by ELK (E: ear-nose-throat; L: lung; 
K: kidney) classification, in which any combina-
tion or singular involvement of the major sites 
can be considered within the disease spectrum 
if supported by the appropriate pathologic or la-
boratory findings (the presence of a cytoplasmic 
antineutrophil cytoplasmic antibodies; cANCA). 
Other less frequently involved organ systems 
include the central and peripheral nervous sys-
tem, skin, muscles, large joints, heart and eyes. 
Rarely, numerous other sites can be affected. 
Virtually any organ can be attacked, and in some 
patients, GPA can manifest unusually. Since 
thoracic involvement of GPA often predomina-
tes, the first who might be expected to establish 
a diagnosis are pulmonary specialists. Therefore, 
they should be aware of those less frequent mani-
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festations, seemingly not compatible with GPA or 
even mimicking other diseases, and keep in mind 
that limited forms of GPA with oligosymptomatic 
and atypical site involvement might occur. Thus, 
this awareness may be also useful when any new 
atypical manifestations occur in the course of 
disease with established diagnosis of GPA. The-
refore, we would like to familiarize pulmonary 
specialists with several extra-ELK involvements 
of the disease.
Breast
Two reviews of the literature showed that 
breast involvement has been rarely reported in the 
literature [4, 5]. The most extensive review of the 
entity has been presented by Allende and Booth 
[4] and included 27 cases reported both in English 
and other languages. In turn, in their systematic 
review, Ren et al. [5] excluded reports published 
in non-English languages and not published in 
peer-review journals, and found 23  relevant ca-
ses. In Poland, two cases of breast involvement 
in GPA with lung and renal manifestations were 
described until now [6, 7]. The majority of cases 
regarded women between the third and seventh 
life decade and accompanied by systemic manife-
stations of the disease [4]. The GPA of the breast 
was usually unilateral and concomitant with lung 
and other organs involvement [8–13], although 
breast lesions can occur as the initial symptom 
of the disease [8, 12]. These lesions presented 
usually as nodules or masses, sometimes poorly 
circumscribed and of a firm consistency, with or 
without extensive necrosis (Figure 1). Such an 
appearance of the lesions resembled neoplastic 
disease of the breast [4, 14–15]. Occasionally, an 
association of a tumor-like lesion of the breast 
with multiple lung nodules strongly suggested 
a presumed diagnosis of metastatic carcinoma 
[12]. In any case, excluding breast carcinoma 
from the clinical differential diagnosis is required.
Skeletal system
Bones are involved in the course of GPA 
very rarely, except for facial bone involvement 
(mainly nasal septum destruction and sclerosing 
osteitis) associated with destructive inflammation 
of nasal passages and sinuses, or temporal bone 
(most often manifested as a mastoiditis). Clinical 
appearance of other bones involvement with GPA, 
concomitantly with lung involvement, has been 
described in single case reports. These include 
a case report presenting a 54-year-old man with 
mass-like lung lesions accompanied by sternal 
osteomyelitis and destructive arthritis around the 
sternoclavicular joint [16]. Initial treatment with 
antibiotics and immunosuppressive therapy was 
non-effective and a new lung lesion occurred. 
A histopathological investigation of the lung mass 
showed chronic granulomatous inflammation 
with fibrinoid necrosis, findings accordant with 
GPA. In other case, granulomatosis with polyan-
giitis affected the scull base and manifested as 
a spontaneous skull base osteomyelitis with the 
development of cranial nerve palsies [17].
Another rare limited form of c-ANCA-po-
sitive GPA started with the bluish discoloration 
of the fingertips of both hands leading to spon-
taneous resorption of digits with acro-osteolysis 
[18]. The lesions were accompanied by general 
symptoms, including intermittent fever, myalgia 
and weight loss with an almost asymptomatic 
solitary cavitating nodule of the lung detected 
on high-resolution chest computed tomography. 
Sequentially, the patient displayed mononeuritis 
multiplex symptoms.
Although facial bone destruction as the most 
frequent bone manifestation of GPA mainly affects 
the nasal septum, contiguous granulomatous 
infiltration may spread to the soft tissues of the 
orbit and/or eye [19].
Orbito-ocular involvement
The orbit and eye are two of the most frequ-
ent body sites that could be affected by both 
granulomatous inflammation and focal ischemic 
vasculitis in the course of GPA. Ophthalmic 
involvement has been reported in up to 60% 
of patients diagnosed with GPA [20]. Orbital 
inflammation and necrotizing keratoscleritis, 
Figure 1. Well-with demarcated large ulceration central necrosis of 
right breast in the course of GPA
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episcleritis or conjunctivitis are the most charac-
teristic presentations. Uveitis and granulomatous 
vasculitis of the retina and optic nerve are also 
relatively common ophthalmic manifestations of 
GPA. In turn, orbital mass is a rare presentation 
in GPA patients. In the study comprising 1,142 
patients with GPA, only 5% developed orbital 
masses during a 5-year follow-up [21]. Howe-
ver, it is noteworthy that profound examination 
initiated by the presence of orbital mass may 
reveal asymptomatic pulmonary lesions [22]. 
Usually, orbito-ocular manifestations represent 
limited form of GPA but can be also the first 
presenting feature of GPA before progression 
to the lung and/or multisystem involvement 
[20, 23]. Thus, pulmonologists may encounter 
cases with pulmonary-renal involvement associa-
ted with initial orbito-ocular symptoms [24]. The 
presence of unexplained orbital inflammatory di-
sease (Figures 2 and 3) in patient with pulmonary 
abnormalities in radiological imaging, should 
raise the question of possible GPA. A thorough 
clinical examination, laboratory testing and hi-
stological examination of lung biopsy specimens 
are essential to diagnose GPA and exclude poten-
tial mimics [25]. In turn, conjunctival ulceration 
as the presentation of GPA is rarely reported, 
and its occurrence in patient with remission of 
the disease may alert renewed systemic disease 
activity [26]. Few case reports have also claimed 
attention to rare orbito-ocular manifestation of 
GPA — acute unilateral dacryoadenitis, which 
may precede upper and lower respiratory tract 
involvement [27–29].
Ophthalmic lesions in the course of GPA 
can result not only from the involvement of soft 
tissues of the orbit but also from the involvement 
of the central nervous system, namely meningeal. 
For instance, because of morphological simila-
rity and the anatomical continuity between the 
meningeal and the perioptic tissues, granuloma-
tous inflammation may spread along such tissue 
planes and even lead to visual loss [24]. In other 
rare cases, optic neuritis in GPA without signs 
of orbital involvement is most likely caused by 
occlusive vasculitis of the vasa nervorum [30]. In 
every case, ocular lesions should be recognized 
as soon as possible so that an early diagnosis may 
allow appropriate treatment and good visual and 
general prognosis.
Nervous system involvement
The involvement of the nervous system by 
GPA, mainly as a peripheral or cranial mono-
neuritis multiplex, occurs relatively frequently, 
affecting 22–53% of patients [31–32]. Involvement 
limited only to the central nervous system (CNS) 
has been reported less frequently, in 2–8% of ca-
ses [32–33]. However, the use of new diagnostic 
Figure 2. Orbit MRI, T1-weighted coronal image showing contiguous 
infiltration which spreads from the ethmoid sinus to the left orbit. 
Some of the oculomotor muscles and optic nerve are infiltrated
Figure 3. Orbit MRI, T1-weighted axial image showing infiltration of 
the right orbit which includes oculomotor muscles
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procedures, including modern neuroimaging, 
allowed detection of CNS involvement in up to 
13% of GPA patients [34].
Three different types of nervous system 
involvement have been enumerated: 1) necroti-
zing vasculitis affecting the cerebral, spinal, and 
radicular vasculature; 2) direct granulomatous 
infiltration from contiguous lesions in the nose, 
paranasal sinuses and orbits; and 3) primary 
necrotizing granulomas in the skull, meninges, 
brain or cranial nerves [35].
The first type is the most common, and both 
peripheral and cranial neuropathies are thought 
to be caused by the small vessels vasculitis [35]. 
Case reports on cranial neuropathies in GPA 
prove the true diagnostics difficulties, because 
sometimes the diagnosis is possible only when 
lung and/or renal extension of GPA follows its 
initial neurological manifestation [36–-38]. Larger 
brain arteries are involved extremely rarely [39]. 
The unique case of GPA with paranasal sinuses, 
pulmonary and renal manifestations, and con-
comitant intracranial aneurysm of the anterior 
choroidal artery, complicated by rupture and 
subarachnoid hemorrhage, has been reported by 
Takei et al. [39]. Necrotizing vasculitis was also 
a pathogenic mechanism of ischemic infarction 
in few case reports [40–41].
Contiguous invasion of granuloma in CNS 
from extracranial sites of GPA, such as nose, pa-
ranasal sinuses and orbits has been incidentally 
described (Figures 4, 5A, 5B) [42]. Most often the 
pathogenic mechanism of lesions found in CNS 
is isolated cerebral or meningeal granulomatous 
inflammation.
Cerebral meningitis is one of the most frequ-
ent manifestations following cerebral ischemic or 
hemorrhagic lesions, observed in 42% of patients 
A B
Figure 5. Brain MRI. A. T1-weighted axial image with contrast enhancement. Images showing contiguous, contrast enhanced infiltration spreads 
from the posterior ethmoid sinus to the cavernous sinus, dura mater and the temporal lobe; B. FLAIR axial image. Local brain edema around imflam-
matory changes is also seen on FLAIR image
Figure 4. Brain MRI, FLAIR axial image showing chronic ischaemic 
stroke of the right hemisphere with retraction of the lateral ventricle. 
The thickening of meninges and frontal sinus inflammation are also seen
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with GPA and CNS involvement [43]. That mani-
festation is considered to represent granulomatous 
infiltration of the dura mater of the brain and be-
cause the leptomeninges (pia and arachnoid) are 
affected incidentally, the terms pachymeningitis, 
hypertrophic pachymeningitis, or chronic hyper-
trophic pachymeningitis are commonly used re-
ferring to this condition. Moreover, whereas such 
neurological manifestations of GPA as mononeu-
ritis multiplex, peripheral neuropathies, ischemic 
stroke, or intracerebral or subarachnoid hemorrha-
ge are quickly put to diagnostic process, headache, 
a common symptom in meningeal involvement is 
often considered a symptom of chronic sinusitis 
or orbital disease. Pachymeningitis in the course 
of GPA may remain unrecognized for a long time 
[44], which in turn, can lead to delay in accurate 
diagnosis and timely treatment preventing serious 
local damage of the CNS. Pulmonologists should 
keep in mind that although pachymeningitis is 
associated with localized form of GPA, in single 
cases it was reported also in patients with lung 
involvement [45–48]. Therefore, in GPA patients 
with recent onset of severe headache, pachyme-
ningitis should be considered and cranial MRI 
performed. This diagnostic procedure may reveal 
general thickening and pronounced enhancement 
of all meningeal structures.
Spinal dural and cord involvement presents as 
a spinal dural mass and in comparison to pachyme-
ningitis, it is reported less frequently, and relapses 
are more often observed [43, 49]. It can be the initial 
GPA manifestation [50] or it can accompany other 
organs involvement, including the lungs, which 
pulmonary specialist should be aware of [49].
Cardiac involvement
Cardiac involvement in GPA is rare and usu-
ally associated with a threat of serious cardiac 
events and clinical courses refractory to immu-
nosuppressive therapy. In the large multicenter 
North American study comprising  517 patients 
with GPA, cardiac involvement was shown in 
3.3% [51]. Generally, all cardiac structures can 
be affected, but the most common cardiac ma-
nifestation in that study was pericarditis (35%) 
followed by cardiomyopathy (30%) and coronary 
artery disease (12%). Less frequent manifesta-
tions included valvular disease (6%) and severe 
conduction disorder (6%) [51]. However, the 
usage of magnetic resonance imaging in the study 
performed by the French Vasculitis Study Group 
revealed that specific cardiac involvement in 
GPA may be underestimated [52]. For instance, 
pericarditis was detected in 26% of all studied 
GPA patients and late gadolinium enhancement, 
mostly nodular, in 32% of subjects. The reason 
for underdiagnosing cardiac manifestations of 
GPA is probably the fact that many of them can 
be subclinical or clinically asymptomatic [53–54]. 
Therefore, cardiac involvement in GPA was stated 
in only few case reports of congestive cardiomy-
opathy [55–57], myocarditis [58–61] and other 
cardiac conditions related to GPA [57, 62–65]. In 
case of coronary arteries involvement, it is note-
worthy that clinically acute coronary syndrome 
in a patient with lung involvement can develop 
with no significant stenosis at catheterization 
[64]. Rhythm problems as a clinical cardiac 
manifestation of GPA with lung involvement 
are infrequent. The most often reported rhythm 
problems are supraventricular arrhythmias, follo-
wed by varying degree of heart block [57, 62–63]. 
Cardiac valvular involvement has been also rarely 
reported but it is a potentially fatal complication 
of GPA. In addition, this cardiac manifestation 
may misleadingly suggest infectious endocar-
ditis [65]. To summarize, pulmonary specialists 
should remember that cardiac involvement in 
a GPA patient is heterogenous and can be usual-
ly clinically nonapparent, although potentially 
life- threatening [63]. They should also take into 
account that stenocardia symptoms or any other 
cardiac symptoms in a patient with suspected 
or confirmed GPA can indicate cardiac involve-
ment. Profuse diagnostics, including magnetic 
resonance imaging, should be performed because 
confirmation of cardiac involvement dictates 
more aggressive treatment.
Systemic and regular cardiac assessment 
in the follow-up of patients with GPA is also 
recommended.
Large vessel vasculitis with or without  
aneurysm formation
Vasculitis of the large vessel with or without 
aneurysmatic changes is not typical finding in 
GPA. However, a review of the literature revealed 
a number of cases in which the involved arteries 
included the aorta [66–74], gastric [75], subcla-
vian [76], pulmonary [74] and internal carotid 
artery [39]. In most instances, depending on the 
artery affected, abdominal pain was the presen-
ting symptom [66, 68, 70–71]. In other cases, back 
pain [69, 72], arm pain [76], headache due to 
subarachnoid hemorrhage [39] and atrioventricu-
lar block were the presenting symptoms. In most 
of the cases, involvement of large vessels was 
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shown simultaneously at the time of diagnosis 
of GPA with pulmonary involvement (Figure 6) 
[39, 68–69, 71–74, 76], but clinical presentation of 
large vessels can manifest several months before 
[66] or after the diagnosis [70].
It seems justifiable to consider GPA in diffe-
rential diagnosis of unexplained abdominal pain 
when aortic aneurysm is found [68, 71]. Especial-
ly, when a young patient presents with abdominal 
aortic aneurysm, GPA may be an underlying cause 
[71]. The early diagnosis is of  great importance, 
because surgical treatment (vascular interven-
tion) and immunosuppressive agents prevent 
a development of further aneurysm, which is 
a life-threatening complication.
Urogenital manifestations of GPA
Urogenital manifestations of GPA are found 
relatively rarely — in less than 1% of patients 
[77–80]. They can be present at the onset of the 
disease, together with lower respiratory system 
manifestations, sometimes as its first clinical evi-
dence (Figure 7). In other cases, they appear before 
subsequent development of pulmonary involve-
ment of GPA or as a symptom of GPA relapse [79, 
81]. Symptomatic urogenital manifestations in 
case reports with concomitant lung involvement 
included prostatitis [79, 82], epididymitis [79, 
81], renal mass [79], ureteral stenosis [82], and 
penile ulceration [83–84]. Some presentations, 
such as a renal or prostate mass, mimic cancer or 
an abscess. Considering GPA in the differential 
diagnosis might help avoiding unnecessary radical 
surgery, especially that urogenital symptoms can 
be promptly resolved with corticosteroids and/or 
immunosuppressive agents.
Endocrine involvement
Endocrine involvement, particularly of the 
thyroid gland, adrenal gland and hypopituitary is 
extremely rare. The single case reports describing 
cold thyroid nodules or suprarenal mass of GPA 
origin and concomitant pulmonary GPA involve-
ments have been published to date [85–87]. Regar-
ding pituitary involvement in GPA, recent search 
for the cases indicated in the literature revealed 
58 published reports. This rare complication more 
frequently affected females (69%) than males [88]. 
Moreover, pituitary involvement has predomi-
nantly concerned posterior gland and is usually 
associated with other organ involvement [88, 
89]. Numerous patients (43–73%) with pituitary 
manifestation of GPA have concomitant lung le-
sions [88, 89]. Cranial diabetes insipidus was the 
most common endocrine abnormality found in 
81% of cases [88]. Anterior pituitary hormone ab-
normalities, including hypogonadism, secondary 
hypothyroidism, hyperprolactinemia and growth 
hormone deficiency, are less frequent. Pulmono-
logists ought to keep in mind the possibility of 
pituitary involvement. In every patient with pul-
monary presentation of GPA who displays unusual 
Figure 6. Axial chest CT scan. Large saccular aneurysm of aortic arch 
and descending aorta adjacent to pulmonary cavitary lesion
Figure 7. Abdominal CT scan. Retroperitoneal inflammatory infiltra-
tion involving iliac vessels and left urether causing hydronephrosis in 
48 years old man with GPA
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symptoms such as polydipsia and polyuria, this 
rare involvement should be considered [90, 91].
Gastrointestinal tract involvement
GPA as a predominantly renopulmonary 
disorder rarely has gastrointestinal system ma-
nifestations and the involvement of this system 
usually occurs long after the onset of initial 
symptoms [92]. Among them, the pancreas, li-
ver or colon involvement is exceedingly rarely 
reported [92–95]. For instance, only single case 
reports described overt clinical manifestation of 
pancreatic GPA, including painless jaundice or 
recurrent acute pancreatitis as an initial presen-
tation of GPA or presentation concomitant with 
the typical pulmonary and/or renal involvement 
[93–94]. Moreover, when a patient with esta-
blished GPA develops otherwise unexplained 
acute pancreatitis, reactivation of the disease 
should be considered by pulmonologists [93]. 
Thus, involvement of the pancreas, although 
uncommon, should be taken into account in 
the differential diagnosis in cases of abdominal 
pain with hyperamylasemia or cases clinically 
mimicking pancreatic carcinoma.
Similarly, liver involvement in GPA is very 
rare with only few case reports in the literature, 
presenting patients with concomitant systemic 
disease affecting the lungs [95]. Though very 
infrequent, this organ involvement is potentially 
fatal due to a risk of liver failure. Therefore, it 
should not be forgotten as a manifestation of GPA.
There are also few case reports of gastric and 
intestinal involvement where severe colitis with 
gastrointestinal hemorrhage was a presenting 
feature of GPA preceding further progression of 
the disease with pulmonary and other organs 
manifestations [92, 96–97]. Other single cases 
reported colitis following initial pulmonary and/
or other organs manifestations of GPA [98–102].
Conclusions
The presented atypical organ involvement 
of GPA does not exhaust the topic of all possible 
manifestations of the disease. Any nonspecific 
illness concomitant with pulmonary lesions in 
GPA patients should raise the suspicion of unusu-
al involvement of the disease, and differential 
diagnostics is required to confirm or exclude this 
suspicion. Understanding of a broad spectrum of 
possible organ involvement in GPA, sometimes 
potentially fatal, may help in timely diagnosis 
and treatment. 
Therefore, collecting data in registry for 
GPA patients (e.g. POLVAS in Poland) and co-
operation among registries, will broaden our 
knowledge about the disease and have impact on 
directions in future research. Proper diagnostics 
of patients with atypical GPA manifestations is 
very important, as it allows the implementa-
tion of  appropriate treatment according to the 
current guidelines of the American College of 
Rheumatology (ACR), as well as British Society 
of Rheumatology and British Health Professionals 
in Rheumatology (BSR and BHPR).
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